- Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Novartis
- Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash CNBC
- Swiss drugmaker Novartis to buy Avidity Biosciences for $12 billion USA Today
- Novartis Said to Near at Least $70-Per-Share Deal for Avidity Bloomberg.com
- Novartis To ‘Bolster’ Neuromuscular Pipeline With $12B Avidity Acquisition BioSpace
Source link